Adaptimmune
OTC: ADAPYAbingdon, Oxfordshire, US · Founded 2008 · 128 employees on LinkedIn · 6 known investors
Find your way into Adaptimmune
Adaptimmune Therapeutics is a biotechnology company, though the specific focus of their therapeutic work is not detailed on this investors and media page.
Founders & leadership
Adaptimmune was founded in 2008 by James Noble.
JN
James NobleChief Executive Officer
AR
GW
Gavin WoodinChief Financial Officer2020–2025He has over thirty years of financial leadership experience, including roles at publicly listed companies on the London and NASDAQ exchanges, and has managed capital raises of approximately $1 billion in equity and debt financing.
WB
William BertrandinChief Operating Offcer2017–2025He has held senior executive roles spanning legal, corporate development, regulatory affairs, and business development across pharmaceutical and biotechnology organizations.
JL
John LungerinChief Patient Supply Officer2019–2025He brings extensive experience in life sciences operations, pharmaceutical supply chain and manufacturing across cell and gene therapies, small molecules, and biologics, along with background in corporate development and mergers and acquisitions; he holds an MBA from the University of Chicago Booth School of Business and graduated from the United States Naval Academy.
EN
Elliot NorryinChief Medical Officer2020–2025
JB
Joanna BrewerChief Scientific Officer
CP
Cintia PiccinainChief Commercial Officer (CCO)2024–2025With more than 20 years of experience in life sciences, she has held leadership roles across biotech and pharmaceutical companies in commercial operations and business development, with expertise in cell and gene therapy, oncology, immunology, and rare diseases.
Board
DM
David MottBoard director
AB
PT
Peter ThompsonBoard director
ES
Investors · 6
Reported raises · per SEC filings
Form D private placements$103.8M disclosed across 1 round · 2014
▶$103.8MraisedOct 2014 · 22 investors · BiotechnologyRule 506(b)
▶$103.8MraisedOct 2014 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David MottDirector
- Ali BehbahaniDirector
- Peter ThompsonDirector
- Elliott SigalDirector
- Dr. Jonathan KnowlesDirector
- James NobleExecutive Officer, Director
- Ian LaingDirector
- Offering amount
- $103.8M
- Amount sold
- $103.8M
- Minimum investment
- $1
- First sale
- Sep 2014
- Incorporated
- Other, United Kingdom
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Cancerresearchuk98 shared keywordsCancer Research UK funds research across discovery, detection, prevention and treatment of cancer to improve patient outcomes and extend survival. It operates as a research funder and scientific organization serving academic and clinical researchers.
Medscape93 shared keywordsMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.
Massive Bio81 shared keywordsMassive Bio operates an AI-based platform that matches cancer patients with oncology clinical trials and provides concierge support throughout the trial process. It serves patients across the U.S., Canada, Latin America, and Europe, and works with pharma and CRO customers, patient advocacy organizations, and the National Cancer Institute's network of cancer centers.
American Cancer Society (ACS)76 shared keywordsThe American Cancer Society is a nonprofit organization that provides cancer research updates, screening and prevention guidance, and community engagement opportunities. It serves individuals seeking cancer information and those who want to support cancer research and patient advocacy efforts.
Companies competing with Adaptimmune for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Adaptimmune do?
- Adaptimmune Therapeutics is a biotechnology company, though the specific focus of their therapeutic work is not detailed on this investors and media page.
- Who founded Adaptimmune?
- Adaptimmune was founded by James Noble in 2008.
- Who are Adaptimmune's investors?
- Adaptimmune's investors include Avoro Capital Advisors, Eight Roads Ventures, F-Prime Capital, Foresite Capital, New Enterprise Associates (NEA), Ridgeback Capital.
- How much funding has Adaptimmune raised?
- Adaptimmune has disclosed $103.8M raised across 1 round.
- Where is Adaptimmune headquartered?
- Adaptimmune is headquartered in Abingdon, Oxfordshire, US.